Non-small cell lung cancer patients who are ineligible for platinum-based chemotherapy benefit from atezolizumab monotherapy.

Published Date: 16 Aug 2023

First-line atezolizumab monotherapy is linked to improved overall survival compared to single-agent chemotherapy in patients with non-small cell lung cancer (NSCLC) who are ineligible for platinum-based chemotherapy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

2.

Non-small cell lung cancer patients who are ineligible for platinum-based chemotherapy benefit from atezolizumab monotherapy.

3.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

4.

Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety

5.

Report provides global picture of wide inequalities in care for women's cancers


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot